OpenAlex
PricingAboutJobs
Log inGet started
Work

Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells

HTML

Year: 2015
Type: article
Source: Radiotherapy and Oncology
DOI: 10.1016/j.radonc.2015.03.028
Authors: Caroline V.M. Verhagen, Rosemarie de Haan, Floor Hageman, Tim P.D. Oostendorp, Annalisa L.E. Carli, Mark J. O’Connor, Jos Jonkers, Marcel Verheij, Michiel W. van den Brekel, Conchita Vens
Institutions: The Netherlands Cancer Institute, AstraZeneca (United Kingdom), Amsterdam UMC Location University of Amsterdam, University of Amsterdam
Language: English

Topic: PARP inhibition in cancer therapy
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: olaparib, PARP inhibitors, radiosensitization, homologous recombination, BRCA2, head and neck squamous cell carcinoma, radiation dose, drug dose dependence, clonogenic survival, combined radiotherapy
SDG: Good health and well-being

Open Access status: closed

Funder: AstraZeneca
OpenAlex ID: W2139285167
FWCI: 6.199
Cites: 37
Cited by: 122
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security